Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Low Dose Mosunetuzumab for Indolent B-Cell Lymphoma
NCT06442475Phase 2Recruiting
- Sponsor
- University of Washington
- Start
- Aug 2024
- Primary completion
- Aug 2027
- Modality
- Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of mosunetuzumab in follicular lymphoma (FL) and marginal zone lymphoma (MZL), sponsored by University of Washington. Primary endpoint: Overall Response at 13 weeks. Started Aug 2024; status: recruiting.
02
Drugs
mosunetuzumab
03
Conditions
follicular lymphoma (FL)marginal zone lymphoma (MZL)
Beyond the preview
Go deeper on NCT06442475.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06442475.